严重的左心室扩张和童年ALCAPA的次要肌肉反:一个病例报告
Christie Villasante-Villalta1, Diego Davila-Flores1, Renee Montesinos-Segura1
1Instituto Nacional Cardiovascular-INCOR, EsSalud, Lima, Peru. Instituto Nacional Cardiovascular-INCOR EsSalud Lima Peru.
Archivos peruanos de cardiologia y cirugia cardiovascular
|January 26, 2026
概括
左冠状动脉来自肺动脉的异常起源 (ALCAPA) 是一种罕见的先天性心脏缺陷. 手术纠正改善了儿科患者的结果,突出了先进的成像和干预的重要性.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 遗传性心脏病是一种先天性心脏病.
- 心血管外科心血管外科
背景情况:
- 左冠状动脉来自肺动脉的异常起源 (ALCAPA) 是一种罕见的先天性心脏缺陷,如果不治疗,死亡率很高.
- 阿尔卡帕可以出现模仿其他心脏病的症状,使诊断复杂化.
研究的目的:
- 在儿科患者中呈现ALCAPA病例.
- 要突出先进的成像技术的诊断实用性.
- 为了强调ALCAPA手术纠正的有效性.
主要方法:
- 一个三岁男孩患有ALCAPA的案例报告.
- 诊断工作包括胸前心声学和心脏计算机断层扫描血管学.
- 外科干预涉及左冠状动脉的再植入和中枢门的修复.
主要成果:
- 这位患者出现呼吸不良,心动减速和体重增加不佳.
- 先进的成像证实了ALCAPA,左心室扩张和心肌吐.
- 成功的手术纠正导致无症状患者在两年随访时保持心脏功能.
结论:
- 早期和准确的ALCAPA诊断对于及时干预至关重要.
- 手术纠正ALCAPA提供了有利的长期结果.
- 这一案例强调了考虑ALCAPA在患有不明原因心脏症状的儿科患者中的重要性.
相关概念视频
Mitral Regurgitation I: Introduction
497
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
497
Mitral Regurgitation III: Medical Management
324
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
324
Mitral Regurgitation IV: Nursing Management
335
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
335
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
443
Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
443
Secondary Active Transport
137.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
137.7K
Cardiomyopathy II: Dilated Cardiomyopathy
548
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
548


